perifosine has been researched along with Multiple Myeloma in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 10 (52.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Amm, J; Tabbara, IA | 1 |
| Orlowski, RZ | 1 |
| Cavallo, F; Genadieva-Stavric, S; Palumbo, A | 1 |
| Iida, S; Ri, M | 1 |
| Chen, J; David, E; Kaufman, JL; Lonial, S; Sinha, R; Sun, SY | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T; Klippel, S; Laubach, JP; McMillin, DW; Mitsiades, CS; Munshi, NC; Richardson, PG | 1 |
| Gajate, C; Mollinedo, F; Reis-Sobreiro, M | 1 |
| Anderson, KC; Cirstea, D; Desai, N; Gorgun, G; Hideshima, T; Ikeda, H; Kapoor, S; Mukherjee, S; Munshi, NC; Patel, K; Perrone, G; Pozzi, S; Raje, N; Rodig, S; Santo, L; Sportelli, P; Vali, S; Vallet, S | 1 |
| Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Schmidt-Hieber, M; Thiel, E; Weimann, A | 1 |
| Allerton, J; Anderson, KC; Bar, M; Colson, K; Densmore, J; Gardner, L; Ghobrial, IM; Hideshima, T; Irwin, D; Jakubowiak, A; Krishnan, A; Laubach, J; Lonial, S; Martin, T; Munshi, N; Poradosu, E; Raje, N; Richardson, PG; Schlossman, R; Sportelli, P; Wolf, J; Zonder, J | 1 |
| Berger, MR; Konstantinov, SM; Reufsteck, C; Yosifov, DY | 1 |
| Anderson, KC; Eng, C; Hideshima, T; Kolesar, J; Richardson, PG | 1 |
| Alsina, M; Anderson, KC; Gardner, L; Giusti, K; Harvey, C; Hideshima, T; Jakubowiak, AJ; Kandarpa, M; Kaufman, JL; Kraftson, S; Poradosu, E; Richardson, PG; Ross, CW; Sportelli, P; Zimmerman, T | 1 |
| Anderson, KC; Catley, L; Chauhan, D; Hideshima, T; Ishitsuka, K; Mitsiades, C; Munshi, NC; Podar, K; Raje, N; Richardson, PG; Yasui, H | 1 |
| Gajate, C; Mollinedo, F | 1 |
| Anderson, KC; Burger, P; Chauhan, D; Fulciniti, M; Ghobrial, IM; Hideshima, T; Leiba, M; Li, XF; Morrison, A; Munshi, NC; Podar, K; Richardson, P; Rumizen, M; Song, W; Tai, YT; Tassone, P | 1 |
| Anderson, KC; Bronson, R; Catley, L; Chauhan, D; Hideshima, T; Munshi, NC; Neri, P; Song, W; Tai, YT; Tassone, P | 1 |
| Anderson, KC; Catley, L; Chauhan, D; Hideshima, H; Hideshima, T; Ikeda, H; Kiziltepe, T; Mitsiades, C; Munshi, NC; Ocio, E; Okawa, Y; Podar, K; Raje, N; Richardson, PG; Tai, YT; Vallet, S; Yasui, H | 1 |
| Alsayed, Y; Anderson, J; Anderson, KC; Ghobrial, IM; Hatjiharissi, E; Hideshima, T; Huston, A; Jia, X; Leleu, X; Moreau, AS; Munshi, N; Ngo, HT; Richardson, P; Roccaro, A; Roodman, DG; Runnels, J; Sportelli, P; Tai, YT; Vallet, S | 1 |
5 review(s) available for perifosine and Multiple Myeloma
| Article | Year |
|---|---|
Emerging therapies in multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Signal Transduction; Thalidomide | 2015 |
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Phosphorylcholine; Piperidines; Proteasome Inhibitors; Pyridines; Remission Induction; Thalidomide; Thiazoles; Treatment Outcome; Vorinostat | 2013 |
New approaches to management of multiple myeloma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Depsipeptides; Frail Elderly; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Pyrazines; Quality of Life; Recurrence; Thalidomide; Treatment Outcome | 2014 |
[Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma].
Topics: Activating Transcription Factor 3; Activating Transcription Factor 4; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase 5; Cytokines; Dexamethasone; DNA-Binding Proteins; Drug Discovery; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Indoles; Kruppel-Like Transcription Factors; Molecular Targeted Therapy; Multiple Myeloma; Nicotinamide Phosphoribosyltransferase; Oligopeptides; Panobinostat; Phosphorylcholine; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Regulatory Factor X Transcription Factors; Toyocamycin; Transcription Factors | 2014 |
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Deacetylases; HSP90 Heat-Shock Proteins; Humans; Immunologic Factors; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyrazines | 2009 |
3 trial(s) available for perifosine and Multiple Myeloma
| Article | Year |
|---|---|
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Phosphorylcholine; Pyrazines; Recurrence | 2011 |
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Phosphatidylinositol 3-Kinase; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Recurrence; Thalidomide; Treatment Outcome | 2012 |
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Differentiation; Cell Proliferation; Cell Survival; Cytotoxins; Dexamethasone; Dose-Response Relationship, Drug; Interleukin-6; Lenalidomide; Ligands; Macrophage Colony-Stimulating Factor; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Neoplasm Transplantation; Osteoclasts; Phosphorylcholine; Pyrazines; RANK Ligand; Stromal Cells; Thalidomide; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2007 |
11 other study(ies) available for perifosine and Multiple Myeloma
| Article | Year |
|---|---|
Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Drug Synergism; Flow Cytometry; Humans; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Receptors, Death Domain; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2008 |
Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Caspase 10; Caspase 8; Cell Line, Tumor; Drug Synergism; fas Receptor; Fas-Associated Death Domain Protein; Flow Cytometry; Fluorescent Antibody Technique; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia, T-Cell; Membrane Microdomains; Microscopy, Confocal; Mitochondria; Multiple Myeloma; Phosphorylcholine; Pyrazines; Resveratrol; Signal Transduction; Stilbenes | 2009 |
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
Topics: Albumins; Animals; Apoptosis; Autophagy; Bone Marrow Cells; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Humans; Insulin-Like Growth Factor I; Interleukin-6; Intracellular Signaling Peptides and Proteins; Mice; Multiple Myeloma; Nanoparticles; Phosphorylation; Phosphorylcholine; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2010 |
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; K562 Cells; Ki-67 Antigen; Lenalidomide; Leukemia, Myeloid; Lymphoma; Multiple Myeloma; Phosphorylcholine; Pyrazines; Thalidomide; Time Factors | 2012 |
Interleukin-6, osteopontin and Raf/MEK/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; MAP Kinase Signaling System; Multiple Myeloma; Organophosphates; Osteopontin; Phosphorylcholine; Proto-Oncogene Proteins c-raf; Quaternary Ammonium Compounds; Signal Transduction; Treatment Outcome | 2012 |
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Drug Evaluation, Preclinical; Fluorouracil; Humans; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyrazines; Randomized Controlled Trials as Topic | 2012 |
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
Topics: Cell Division; Cell Line, Tumor; Flow Cytometry; Growth Substances; Humans; Multiple Myeloma; Oncogene Protein v-akt; Phosphorylation; Phosphorylcholine | 2006 |
Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.
Topics: Apoptosis; Caspase 8; Cell Line, Tumor; Cell Proliferation; fas Receptor; Fas-Associated Death Domain Protein; Humans; Membrane Microdomains; Multiple Myeloma; Phospholipid Ethers; Phosphorylcholine; Signal Transduction; Structure-Activity Relationship | 2007 |
Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model.
Topics: Animals; Apoptosis; Cell Line; Female; Hematopoiesis; Humans; Hyperplasia; Leukocytosis; Mice; Multiple Myeloma; Myeloid Cells; Phosphorylcholine; Thrombocytosis | 2007 |
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Inhibitor of Apoptosis Proteins; Mice; Microtubule-Associated Proteins; Models, Animal; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Phosphorylcholine; Protease Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; RNA Interference; RNA, Small Interfering; Survivin; Transplantation, Heterologous | 2007 |
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.
Topics: Benzoquinones; Bone Marrow; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; DNA Replication; Flow Cytometry; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt | 2008 |